Sam Philip Heywood

USPTO Granted Patents = 24 (Patent Applications = 7)

CIPO Patents = 9 (Patent Applications = 8)

EPO Patents = 13 (Patent Applications = 17)

Average Co-Inventor Count = 3.0

ph-index = 6

Forward Citations = 111(Granted Patents)

Location History:

High Wycombe, GB (2011)
Berkshire, GB (2019 - 2022)
Slough, GB (2013 - 2023)

Company Filing History:

Years Active: 2011-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428497 - Multispecific antibody constructs (2025-09-30),

2. 11834514 - Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species (2023-12-05),

3. 11786593 - Method of monomerisation of recombinant antibody molecules (2023-10-17),

4. 11466076 - Binding domain or antibody specific to a human serum albumin (HSA) (2022-10-11),

5. 11427650 - Dual specificity antibody fusions (2022-08-30),

6. 11401349 - Single linker FabFv antibodies and methods of producing same (2022-08-02),

7. 11345760 - Multispecific antibody constructs (2022-05-31),

8. 11091542 - Antibody molecules which bind TNF alpha (2021-08-17),

9. 10927164 - Method for protein purification (2021-02-23),

10. 10829565 - Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species (2020-11-10),

11. 10828366 - Method of monomerisation of recombinant antibody molecules (2020-11-10),

12. 10472426 - Disulfide stabilized DVD-Ig molecules (2019-11-12),

13. 10457748 - Single linker FabFv antibodies and methods of producing same (2019-10-29),

14. 10407513 - Biological products (2019-09-10),

15. 10100130 - Dual specificity antibody fusions (2018-10-16),

Title: **Sam Philip Heywood: Innovation in Antibody Technologies**

Introduction

Sam Philip Heywood, an accomplished inventor located in Slough, GB, has made significant contributions to the field of biotechnology, specifically in antibody production. With an impressive portfolio of 23 patents, his work exemplifies the dedication to innovation and excellence in research and development.

Latest Patents

Some of Heywood's latest patents include groundbreaking methods designed to enhance the efficacy of recombinantly expressed antibody molecules. The first patent, titled “Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species,” details a process that increases the percentage of monomers in a composition of antibody molecules. This process involves a thermal conversion step that takes place at temperatures between 30 to 60°C while utilizing a reducing agent.

The second patent, “Method of monomerisation of recombinant antibody molecules,” also focuses on improving the monomer percentage in antibody compositions. It involves the treatment of the antibody composition with a denaturant, such as urea or Guanidine hydrochloride, again in the presence of a reducing agent. These innovative methods hold the potential for significant advancements in therapeutic antibody development.

Career Highlights

Throughout his career, Heywood has worked with reputable organizations, including UCB Biopharma Sprl and UCB Biopharma SRL. His experience at these institutions has enabled him to refine his expertise in the field and contribute to cutting-edge research in antibody technology.

Collaborations

In his journey through the industry, Heywood has collaborated with notable figures such as David Paul Humphreys and Emma Dave. These partnerships have likely played a pivotal role in the development and validation of his patents, further enriching the field of biotechnology.

Conclusion

Sam Philip Heywood stands out as a significant innovator within the biotechnology sector, exemplified by his extensive patent portfolio and collaborative efforts. His contributions to improving the production and efficacy of antibody molecules will undoubtedly have a lasting impact on biopharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.